This proposal represents a request for continued funding of the NIH-sponsored Clinical Pharmacology Fellowship Training Program at the Mayo Clinic-Mayo Clinic College of Medicine-Mayo Medical School. This research training experience is integrated within a broad curriculum that exposes Trainees to critical aspects of the science underlying Clinical Pharmacology ~ all within a supportive, mentoring environment. Clinical Pharmacology represents a """"""""bridge discipline"""""""" that is devoted to the study of the interaction between humans and drugs. Within the context of the ongoing"""""""" revolution"""""""" that is occurring in biomedical science, a revolution that promises to transform medical practice, Clinical Pharmacology lies at the confluence of the disciplines of molecular pharmacology, genomics, proteomics, bioinformatics and rational therapeutics - with an ultimate goal of scientifically """"""""individualized"""""""" drug therapy. Therefore, Clinical Pharmacology seeks to enhance our understanding of the molecular basis for drug response and to apply that information at the translational interface to make it possible to tailor drug therapy to both the underlying disease process and the unique characteristics of each individual patient. However, our ability to take advantage of this unique opportunity will require that we train a new generation of Clinical Pharmacologists in science that is based on a foundation provided by the """"""""new biology"""""""". Large, comprehensive, integrated academic medical centers like the Mayo Clinic are ideally positioned to train this new generation of Clinical Pharmacologists. Mayo is able to do that because of its long history of integrating basic and clinical medical research, because of a long tradition of contributing to the discipline of Clinical Pharmacology, because the Mayo Clinical Pharmacology Training Program has had decades of experience in successfully recruiting and training physician scientists and because of an historical focus at Mayo on translational science. The Mayo Clinical Pharmacology Fellowship Training Program will continue to emphasize strong laboratory-based research training, systematic exposure to clinical science, and a structured mentorship - with the goal of preparing each Fellow to become a future leader in Clinical Pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008685-14
Application #
8092731
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PG))
Program Officer
Okita, Richard T
Project Start
1998-07-01
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
14
Fiscal Year
2011
Total Cost
$282,556
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ahmed, Ahmed T; Weinshilboum, Richard; Frye, Mark A (2018) Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder. Clin Pharmacol Ther 103:767-769
Cairns, Junmei; Fridley, Brooke L; Jenkins, Gregory D et al. (2018) Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation. EMBO Rep 19:
Kohorst, Mira A; Warad, Deepti M; Nageswara Rao, Amulya A et al. (2018) Obesity, sedentary lifestyle, and video games: The new thrombophilia cocktail in adolescents. Pediatr Blood Cancer 65:e27041
Ahmed, Ahmed T; Frye, Mark A; Rush, A John et al. (2018) Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. J Affect Disord 238:1-7
Yan, Yiyi; Kumar, Anagha Bangalore; Finnes, Heidi et al. (2018) Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol 9:1739
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Eugene, Andy R (2017) CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly based on Nonparametric Population Pharmacokinetic Modeling and Simulations. Int J Clin Pharmacol Toxicol 6:242-249
Eugene, Andy R; Masiak, Jolanta (2017) A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy. Nord J Psychiatry 71:417-424
Elraiyah, T; Jerde, C R; Shrestha, S et al. (2017) Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population. Clin Pharmacol Ther 101:382-390

Showing the most recent 10 out of 61 publications